The company holds and licenses a variety of IP related to high-throughput genotyping, sample pooling, and methods involved in oligonucleotide ligation-based assays.
The technology uses a proprietary chemistry that attaches primers to probes with a polyethylene glycol-based linker to prevent the formation of primer-dimers.
Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.
